SCHEMBL2086764

SCHEMBL2086764

O=C(O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Br)cnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.49
NPC1 O15118 6/20 0.49
KDM4E B2RXH2 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
RXFP1 Q9HBX9 1/20 0.44
KDR P35968 2/20 0.40
BRS3 P32247 1/20 0.39
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
GPR119 Q8TDV5 2/20 0.36
GRIK1 P39086 1/20 0.36
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2083955 0.88 RAB9A (0.51) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4275323 0.87 RAB9A (0.57) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4272298 0.85 RAB9A (0.61) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4126386 0.85 KMO (0.39) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4127132 0.84 RAB9A (0.47) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4115998 0.83 CNR1 (0.49) KDM4ESMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL2086361 0.82 ERAP1 (0.45) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4120614 0.81 SMN1; SMN2 (0.35) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL2085521 0.80 ERAP1 (0.38) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1
SCHEMBL4115065 0.80 RAB9A (0.52) RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921380-B2 Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-12-30 US disclosed
EP-2035427-B1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORP (JP) 2013-12-11 EP disclosed
EP-2520577-A1 Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists Mitsubishi Tanabe Pharma Corporation (JP) 2012-11-07 EP disclosed
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST TANIMOTO KOICHI (JP) 2012-08-09 US disclosed
US-8163759-B2 Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-04-24 US disclosed
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202992-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR RAB9A 424/4885NPC1 3764/4885KDM4E 1550/4885
US-20090258867-A1 PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST CNR1, CNR2, CCKAR RAB9A 426/4885NPC1 3892/4885KDM4E 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.